Antibiosis of Necrotizing Pancreatitis by Arlt, Alexander et al.
 
 
 
 
 
Dieses Dokument ist eine Zweitveröffentlichung (Verlagsversion) / 
This is a self-archiving document (published version):  
 
 
 
 
 
 
 
 
 
 
Diese Version ist verfügbar / This version is available on:  
https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-716827 
 
 
 
„Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFGgeförderten) Allianz- bzw. 
Nationallizenz frei zugänglich.“ 
 
This publication is openly accessible with the permission of the copyright owner. The permission is granted 
within a nationwide license, supported by the German Research Foundation (abbr. in German DFG). 
www.nationallizenzen.de/ 
 
    
 
Alexander Arlt, Wiebke Erhart, Clemens Schafmayer, Hanns-Christoph Held, 
Jochen Hampe 
Antibiosis of Necrotizing Pancreatitis 
 
Erstveröffentlichung in / First published in: 
Viszeralmedizin. 2014, 30(5), S. 318 – 324 [Zugriff am: 29.04.2020]. Karger. ISSN 1662-6672.  
 
DOI: https://doi.org/10.1159/000367948 
 
   
Fax +49 761 4 52 07 14
Information@Karger.com
www.karger.com
Accessible online at: 
www.karger.com/vim
Review Article · Übersichtsarbeit
Viszeralmedizin 2014;30:318–324
DOI: 10.1159/000367948
Antibiosis of Necrotizing Pancreatitis
Alexander Arlt a  Wiebke Erhart a  Clemens Schafmayer b  Hanns-Christoph Held c   
Jochen Hampe d 
a
 Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany, 
b
 Department of General and Thoracic Surgery, University Hospital Schleswig-Holstein, Kiel, Germany, 
c
 Department of General, Thoracic and Vascular Surgery, University Hospital Dresden, Dresden University of Technology, Dresden, Germany, 
d
 Department of Internal Medicine I, University Hospital Dresden, Dresden University of Technology, Dresden, Germany
Schlüsselwörter
Nekrotisierende Pankreatitis · Antibotika · Pilzinfektion ·  
Mikrobiota
Zusammenfassung
Hintergrund: Die nekrotisierende Pankreatitis weist eine Mor-
talität von 20–80% auf. Initial ist vor allem das Ausmaß des 
Organversagens entscheidend für die Prognose des Patien-
ten. In der zweiten Krankheitswoche stellt dann die sekundäre 
Infektion der Nekrosen durch die Translokation von Darmkei-
men das entscheidende Problem dar. Zur Vermeidung einer 
solchen Infektion werden klinisch sehr häufig Breitspektrum-
antibioktika prophylaktisch eingesetzt. Dies wird aber zu-
nehmend kritisch diskutiert, und es existieren kontroverse 
 Empfehlungen. Methoden: Eine Literaturrecherche unter Ein-
beziehung von PubMed und der Programme der Digestive 
 Disease Week (DDW) und der United European Gastroente-
rology Week (UEGW) wurde durchgeführt. Ergebnisse: Die 
meisten Studien können den prophylaktischen Einsatz von 
Antibiotika bei der schweren Pankreatitis nicht rechtfertigen. 
Einige Studien belegen vielmehr eine Selektion resistenter 
Keime und vor allem auch eine erhöhte Rate von schwer 
 therapierbaren Pilzinfektionen unter einer solchen Therapie. 
Daher sollte erst nach dem Nachweis einer Nekroseinfektion 
mit einer Antibiotikatherapie begonnen werden, wobei keine 
Routine-Feinnadelpunktion der Nekrose zum Keimnachweis 
durchgeführt werden sollte. Es stehen daher nur indirekte, 
meist bildgebende Verfahren für den Infektionsnachweis zur 
Verfügung. Entscheidende Faktoren wie die enterale Ernäh-
rung und die Methode der Nekrosektomie wurden bisher bei 
den meisten Studien vernachlässigt, scheinen aber essenziell 
für das Behandlungsergebnis des Patienten zu sein. Schluss-
folgerungen: Die meisten publizierten Studien weisen eine 
sehr heterogene Definition der Erkrankung, uneinheitliche Be-
handlungsprotokolle und Ungenauigkeiten bei der statisti-
schen Testung auf. Gerade entscheidende Faktoren wie die 
enterale Ernährung werden größtenteils komplett vernachläs-
sigt. Es besteht daher ein Bedarf für randomisierte placebo-
kontrollierte Studien, die diese Probleme berücksichtigen und 
suffiziente Schlussfolgerungen zur Antibiotikatherapie der 
schweren Pankreatitis zulassen.
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Summary
Background: Necrotizing pancreatitis is a life-threatening 
presentation of acute pancreatitis. The mortality of 20–80% 
initially depends on the persistence of organ failure and sys-
temic inflammatory response syndrome (SIRS) and, in the 
later course of the disease, on secondary infection of the ne-
crosis. The questions whether prophylactic antibiotics aiming 
to prevent this infection should be administered and which 
antibiotic is the best to use, as well as the problem of fungal 
infection under antibiotic treatment are still intriguing and in-
sufficiently solved. Methods: A search of the literature using 
PubMed was carried out, supplemented by a review of the 
programmes of the Digestive Disease Week (DDW) and the 
United European Gastroenterology Week (UEGW). Results: 
Despite the widely practised prophylactic antibiotic adminis-
tration in severe pancreatitis, no evidence for the benefit of 
this strategy exists. One of the drawbacks might be a ten-
dency for disastrous fungal infection under prophylactic anti-
biotics. Bacterial translocation from the gut in the second 
week after the onset of symptoms is the major source for in-
fection of pancreatic necrosis and provides a clear indication 
for antibiotic treatment. However, routine fine-needle aspira-
tion for a calculated antibiotic therapy cannot be recom-
mended, and all other tests offer only indirect signs. Impor-
tant factors such as enteral versus parenteral feeding and the 
method of necrosectomy are mostly neglected in the trials 
but seem to be essential for the outcome of the patient. Con-
clusions: Even though most meta-analyses including the 
newer double-blind, placebo-controlled trials on prophylactic 
antibiotics showed no beneficial effects in the prevention of 
infection of necrosis and/or outcome of the patients, this 
strategy is still widely used in clinical routine. Since nearly all 
trials published so far show systematic problems (i.e. inaccu-
rate definition of the severity of the disease, poor statistical 
testing, and neglect of differences in the route of nutrition), 
there is a need for randomized controlled prospective trials 
with exact definitions of the disease.
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Introduction
Acute pancreatitis is one of the most common acute gas-
trointestinal diseases requiring hospitalization. The mortality 
rate of the disease is very heterogeneous, ranking from 
nearly 0% in case of a mild pancreatitis up to 80% in cases of 
a severe necrotizing pancreatitis [1]. The revision of the At-
lanta classification (schematic presentation given in fig. 1) 
recently addressed this aspect of very diverse subgroups and 
defined three grades of severity for acute pancreatitis based 
on the presence and persistence of an organ failure and 
clearly described groups with regard to the presence/distri-
bution of pancreatic necrosis [1]. Shortly after symptom 
onset, the presence of organ failure, e.g. renal dysfunction, 
determines the outcome of the patients [2] and can be used 
to stratify the patients in clinical treatment groups. In this 
initial phase of the disease, the presence of pancreatic necro-
sis is only of marginal importance for the treatment strate-
gies even if the impact of the localization of the necrosis was 
highlighted in a recent manuscript, showing that patients 
with exclusive extrapancreatic fluid collections have a far 
better prognosis compared to those with parenchymal necro-
sis [3]. As mentioned above, the revised Atlanta classifica-
tion defines necrotizing pancreatitis by the presence of ei-
ther pancreatic parenchymal or only peripancreatic necrosis 
[1]. In approximately 30% of the patients an infection of the 
necrosis occurs [3], requiring intervention and resulting in a 
worse prognosis compared to the patients without infected 
necrosis. Prophylactic antibiotic administration is widely 
practised. However, there is a plethora of contradicting data 
for such an approach. First of all, there is no clear evidence 
that prophylactic antibiotics improve the patient outcome. 
Furthermore, the problem of fungal infection under prophy-
lactic antibiotic administration is still a matter of concern. 
Infection of necrosis is mostly defined by clinical signs. The 
value of routine fine-needle aspiration and/or systemic blood 
sampling for the detection of infection is still ambiguous. Fi-
nally, in the last couple of years, growing evidence indicates 
that the enteral route of feeding is able to prevent or at least 
to reduce infection of necrosis and that minimally invasive 
necrosectomy significantly influences the patient’s outcome. 
This review will give an overview of the existing data con-
cerning antibiotic therapy of necrotizing pancreatitis. Since 
there are several meta-analyses of prophylactic antibiosis, 
we will build on these reports. Thereafter, we highlight im-
portant aspects of antibiosis in pancreatitis and illustrate 
why the existing data fail to sufficiently support prophylactic 
antibiotic treatment strategies.
Recommendations for/against Prophylactic  
Antibiosis
Since most patients with severe acute pancreatitis clinically 
present with symptoms like fever and very high levels of in-
flammatory markers such as C-reactive protein (CRP) and 
procalcitonin [4–6], there is a tendency to administer broad-
spectrum antibiotics in the initial phase of the disease despite 
existing guidelines [7, 8]. Besides the inflammatory markers 
and the clinical status of the patients, the knowledge that, in 
addition to organ failure, infection of the necrosis is the criti-
cal determinant for the prognosis of the patient leads to the 
assumption that a prophylactic antibiotic treatment could be 
beneficial [9].
Type of pancreatitis Collections <4 weeks Collections >4 weeks
Interstitial
(85%)
APFC (acute pancreatic fluid 
collection)
sterile
infected
Pseudocyst
- sterile
- infected
- no solid material
Necrotizing
(15%)
ANC (acute necrotic collection)
- solid material 
- parenchymal and/or
peripancreatic tissue
- sterile/infected
WON (walled-off pancreatic necrosis)
- mature, encapsulated necrotic 
collection with well defined wall
- sterile/infected
- parenchymal/peripancreatic/distant
from pancreas
Acute pancreatitis
Diagnosis: Lipase and clinical signs   
Assessment of severity:
Marshall score (or others) – high 
dependency on renal function
No CT in the first 48 h!
Mild pancreatitis: no organ failure and no complications
Moderately severe acute pancreatitis: transient (<48 h) organ failure and/or complications
Severe acute pancreatitis: persistent (>48 h) organ failure
Assessment of morphological features
((endo-)sonography/CT/MRT)
Fig. 1. Schematic 
presentation of the 
diagnostic algorithm 
of the revised Atlanta 
classification [1].
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However, the data for the outcome of the patients receiv-
ing prophylactic antibiosis are conflicting. In this review, we 
will summarize meta-analyses and reviews on this issue [10–
34] (please also refer to table 1 for a short summary of the in-
cluded meta-analyses) and will not discuss the original data in 
detail.
Over the last decade, there was a change in the recom-
mendation of prophylactic usage of antibiotics. Nearly all 
studies, meta-analyses, and reviews before 2004 showed the 
superiority of prophylactic antibiosis [31–33, 35]. Due to an 
improvement of the quality of the studies (e.g. more exact 
definition of severe pancreatitis and greater patient numbers 
enrolled) there was a shift to a more restrictive administra-
tion only after confirmation of infection of the necrosis. One 
of the landmark studies leading to this shift was one of the 
first placebo-controlled, double-blinded trials by Isenmann 
et al. [36]. This work showed no differences in the rate of in-
fected pancreatic necrosis, systemic complications, or mor-
tality between the placebo and the ciprofloxacin/metronida-
zole arm. However, as discussed later, the choice of antibiot-
ics in this study could be questioned, and there are still meta-
analyses and reviews that support a prophylactic antibiotic 
strategy [16–18, 22, 24, 27, 28, 31, 32]. Mostly depending on 
publication date, these studies either recommend prophylac-
tic antibiosis because of a general outcome benefit (meta-
analyses of studies before 2004) or they outline advantages 
for subgroups or specific problems without advantages re-
garding mortality. In 2001, Bassi et al. [32] concluded that 
prophylactic antibiotics reduce the incidence of infected ne-
crosis and pancreatic abscesses during severe pancreatitis 
and that this approach was the only one tested at the time in 
several randomized studies. However, the authors suggested 
that a combination of broad-spectrum antibiotics, selective 
digestive decontamination, and enteral nutrition might be 
beneficial in severe pancreatitis [32]. For selective intestinal 
decontamination, there is a controlled clinical trial reporting 
a reduced mortality [37]. 
The route of nutrition might have influenced the patients’ 
outcome in these trials on prophylactic antibiotic use, as dis-
cussed later. In the same year, another meta-analysis con-
cluded that prophylactic administration of antibiotics with 
proven efficiency in necrotic pancreatic tissue should be given 
to every patient with severe pancreatitis because of a general 
reduction of sepsis and mortality in all patients [31]. The 
choice of the antibiotics might explain some of the contro-
versy in the field as well as in meta-analyses. In 2006, a 
Cochrane review concluded that antibiotic prophylaxis signifi-
cantly reduces mortality and infection of pancreatic necrosis 
when beta-lactams were used [27]. Quinolone plus imidazole 
regimens were not effective, and the authors clearly criticized 
the quality of the existing studies and recommended better 
designed studies that directly compare different antibiotics 
Table 1. Summary of the meta-analyses discussed in this review
Author Year Necrosis 
infection
Non-necrosis  
infection
Length  
of stay
Survival  
mortality
Comments
Golub et al. [33] 1998 n.a. n.a. n.a. + only if broad-spectrum AB were 
used
Gumaste [35] 2000 + n.a. n.a. n.a. imipenem was the most promising 
AB
Sharma and Howden [31] 2001 (+) n.a. n.a. + general recommendation for AB
Mazaki et al. [29] 2006 – – + –
Villatoro et al. [27] 2006 ± n.a. n.a. + beta-lactams also reduce infection
Xiong et al.a [26] 2006 – n.a. n.a. –
Bai et al.a [40] 2008 – n.a. n.a. –
Hart et al. [24] 2008 – + + –
Wittau et al.a [23] 2008 – n.a. n.a. – discussed the shortcomings of trials 
supporting AB
Xu and Cai [22] 2008 + + + – carbapenems are superior
Jafri et al. [20] 2009 – + – –
Segarra-Newnham and  
Hough [19]
2009 ± ± ± ± heterogeneity of trials; on demand 
use of AB after confirmation of  
infection
Villatoro et al.a [17] 2010 – – – – none of the studies were sufficiently 
powered
Yao et al. [16] 2010 + – – –
Wittau et al.a [12] 2011 – – n.a. –
Jiang et al.a [10] 2012 n.a. n.a. n.a. – subgroups might benefit
aMeta-analysis showing no beneficial effects of prophylactic antibiotics at all.
+ = Positive influence of prophylactic antibiotics; – = no effect of prophylactic antibiotics; n.a. = not analyzed; AB = antibiotics.
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[27]. However, the same group of authors revisited this issue 
in 2010 and found no beneficial effects of the antibiotics on 
infection of necrosis or death [29]. Even after the publication 
of the first double-blind, placebo-controlled trials in 2004 and 
2007 [36, 38], showing nearly no effects of the prophylactic an-
tibiotics, two meta-analyses concluded that prophylactic anti-
biotic treatment is associated with a significant reduction of 
pancreatic or peripancreatic infection, non-pancreatic infec-
tion, and length of hospital stay [22, 24]. However, neither a 
reduced mortality nor a lower frequency of surgical interven-
tion was observed in these analyses. In contrast, a recent 
meta-analysis showed a general reduction of infection of in-
trapancreatic necrosis and, in a subgroup analysis, a beneficial 
effect of prophylactic antibiotics on infection of necrosis in 
general and also on mortality in single-blinded randomized 
controlled trials (RCTs) [16].
As already mentioned, in the beginning of this century 
there was a shift in the results of the trials on prophylactic an-
tibiotics. In 2012, a meta-analysis of 11 RCTs showed by 
means of a subgroup analysis that there was a significant re-
duction of the mortality rate in the period before 2000, while 
no significant reduction occurred in the period from 2000 on-
wards [10]. The authors further reasoned that there might 
have been an apparent publication bias in the period before 
2000 but that certain patients with severe pancreatitis could 
still benefit from antibiotic prophylaxis. In line with this meta-
analysis, nearly all new but also some older reviews and meta-
analyses [10, 12, 17, 19–21, 23, 25, 29, 30, 39, 40] conclude that 
a general recommendation for prophylactic antibiotics cannot 
be given. Most of these authors also see a need for better tri-
als since some subgroups might benefit from antibiotics. One 
interesting point was addressed by a group of authors from 
Pakistan [18]. They stated that in developing countries the 
cost needed for managing complications of pancreatitis might 
be a limiting factor, and since prophylactic antibiotics could 
be beneficial in selected cases, they should be applied early in 
the course of the disease [18].
Microbiology of Infection in Acute Severe  
Pancreatitis
In general, acute pancreatitis is a disease which is not medi-
ated by microbiota, and the initial high values for inflamma-
tory markers like CRP and procalcitonin are signs of a sys-
temic inflammatory response syndrome (SIRS) and might 
predict the outcome of the patients; however, they are not 
markers for an infection [4–6]. Translocation of bacteria from 
the small bowel 7–14 days after the onset of pancreatitis is 
thought to be the major source for infection of necrosis [41], 
highlighting the importance to maintain the barrier function 
of the gut [42] through early enteral feeding [43, 44]. A recent 
single-centre study of 51 consecutive patients in India showed 
that there might be differences in the bacteriology of pancre-
atic and peripancreatic infections [45]. Pancreatic infections 
were more often monomicrobial with a shift from Gram-nega-
tive to Gram-positive microbes as the pancreatitis progressed. 
Extrapancreatic infections were more often polymicrobial. 
Most commonly, the blood stream was invaded by Gram-pos-
itive bacteria, and another study showed a correlation be-
tween the bacteria isolated from the blood and the severity of 
the disease [46].
Which Is the ‘Right’ Compound for Antibiotic  
Therapy of Pancreatitis
Some meta-analyses and reviews suggested a possibility 
that the lack of clinical benefit of prophylactic antibiotics in 
some RCTs could be attributed to the usage of a non-effective 
compound [27, 35]. Several preclinical and clinical studies an-
alysed the penetration of antibiotics in the pancreatic tissue 
and/or pancreatic juice to predict their effectiveness in the 
treatment of necrosis infection [47–56]. However, such a pre-
diction has clear limitations, as demonstrated by the example 
of imipenem versus pefloxacin [48, 49]. In a study trying to 
predict the effectiveness of antibiotics in pancreatitis, pefloxa-
cin or metronidazole was superior to imipenem with regard to 
antimicrobial activity, penetration rate, persistence, and ther-
apeutic concentration in the necrotic pancreatic area [49]. In 
contrast, in the follow-up controlled clinical trial pefloxacin 
was inferior to imipenem in the prevention of infections [48]. 
Since such RCTs comparing different antibiotics against each 
other and against placebo are nearly completely lacking, the 
rather aged recommendation for imipenem as the antibiotic 
of choice is still widely practiced in clinical routine [17, 18, 35, 
57].
Fungal Problematic
The usage of antifungal prophylaxis has been debated 
without any clear tendencies for the last 15 years [58–63]. The 
fact that fungal infection, most often caused by Candida spe-
cies, is a predictor for a worse outcome in necrotizing pancre-
atitis is widely established [59, 60, 63]. Especially antibiotic 
treatment promotes the overgrowth of unaffected microor-
ganism and is thought to be a major risk factor for fungal in-
fection [59, 60, 64]. Thus, there is an ongoing debate whether 
an antifungal prophylaxis should be generally combined with 
prophylactic antibiotics [14, 58–60, 62]. Up to now, no ran-
domized trial on prophylactic fungal therapy in pancreatitis 
exists. As in the case of prophylactic antibiotics, several other 
factors such as the route of feeding and drainage of necrosis 
might be crucial for the outcome of the patient and could 
spare the need for an antimicrobial treatment in general as 
well as an antifungal prophylaxis, which could additionally se-
lect multiresistant subspecies [60, 62].
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Diagnosis of Infection
Based on the existing double-blind randomized trials, anti-
microbial therapy can only be recommended after confirma-
tion of infection of necrosis [7, 8]. One of the existing gold 
standards, i.e. fine-needle aspiration, was recently challenged 
by van Baal et al. [65].
The authors demonstrated that based on clinical and imag-
ing signs (gas bubbles in computed tomography) the diagnos-
tic accuracy for infection of the necrosis and most importantly 
the outcome of the patients did not differ from the group re-
ceiving a fine-needle aspiration. However, especially the clini-
cal signs are not well defined and include persisting sepsis, 
(new or prolonged) organ failure, increased need for cardio-
vascular and/or respiratory and/or renal support, leukocytosis, 
increased levels of CRP, and fever. Moreover, no other infec-
tious focus must be found or held responsible for the clinical 
deterioration. Radiological signs such as the inclusion of air in 
the diagnosis of infection of necrosis were already established 
in other studies [1]. New 16S-based techniques might offer the 
required sensitivity and specificity for early detection of gen-
eral bacteraemia [46] and might also be a tool for prediction 
of necrosis infection. The content of liquid in the necrosis 
might predict the need for intervention in general but might 
also define a subgroup that benefits from antimicrobial ther-
apy [66].
Enteral Feeding and Therapy of the Infected  
Necrosis
In acute pancreatitis, the infection of necrosis is the major 
determinant for the outcome of the patient after the initial 
phase. Not only prevention of necrosis infection but also im-
proved treatment of infected necrosis significantly influence 
any prophylactic antimicrobial strategy and must be included 
in the design of RCTs. Early enteral feeding, which is known 
to prevent bacterial translocation through stabilization of the 
gut barrier and motility, has been shown to be effective in the 
prevention of infection and to be beneficial for the overall 
outcome in acute pancreatitis [44, 67]. Since the aspect of nu-
trition was poorly addressed in the RCT on prophylactic anti-
biotics, studies comparing antibiotics with placebo in a fixed 
setting of early enteral nutrition are needed. In addition, the 
outstanding work of the Dutch Pancreatitis Study Group 
clearly showed that a minimally invasive step-up approach in 
the treatment of infected necrosis is superior to open surgery, 
resulting in lower morbidity and mortality [43, 68]. Upcoming 
trials of this and other groups might further disclose if mini-
mally invasive laparoscopy or endoscopy should be preferred 
in the treatment of the necrosis [69].
Conclusions
Based on the placebo-controlled trials and the recent meta-
analyses on prophylactic antibiosis in necrotizing pancreatitis, 
antibiotic therapy with a broad-spectrum antibiotic like imi-
penem should be started only after confirmation of infection 
of the necrosis. However, nearly all authors concluded that 
the existing trials have several shortcomings and clearly 
voiced the need for better placebo-controlled trials. Such tri-
als have to address several points:
Exact Definition of the Necrosis and Infection
Since the localization of the necrosis (i.e. peripancreatic vs. 
mixed) is influencing the outcome of the patient indepen-
dently, this information must be considered in the inclusion/
exclusion criteria. In addition, incidence of infection of necro-
sis is one of the central questions of these trials and, as dis-
cussed above, only poorly defined by non-invasive techniques.
Early Enteral Nutrition
As early enteral nutrition has been shown to significantly 
reduce the rate of infection of necrosis and to improve the 
outcome of the patients, the route of nutrition must be in-
cluded in the study protocol.
Choice of Antibiosis
Currently, imipenem seems to be the most potent antibi-
otic but nearly no data comparing antibiotics directly are 
available. Based on empirical clinical knowledge, however, we 
would suggest that any conducted trial should include an imi-
penem group besides the placebo group. 
Prophylactic Antifungal Therapy
One argument against prophylactic antibiotics in necrotiz-
ing pancreatitis is the selection of resistant microbiota, espe-
cially Candida spp. Therefore, trials on antibiotics should also 
include groups receiving a prophylactic antifungal therapeutic 
like caspofungin or amphotericin B besides the antibiotic 
agent.
Therapy of Infected Necrosis
If the overall outcome of the patient is included in the 
study protocol, the method of draining the infected necrosis 
must be included since the minimally invasive approach has 
been shown to be superior to open surgical procedures.
Although several other important points could be listed, 
these five aspects already highlight the need for multicentre, 
placebo-controlled studies including high numbers of patients. 
In the recent past, the Dutch Pancreatitis Study Group showed 
how such studies could change the therapeutic approach to se-
verely ill patients suffering from necrotizing pancreatitis and 
dramatically improve their outcome. Therefore, we hope that 
at least some of the points raised in this review will be ad-
dressed by appropriately designed trials in the near future.
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